YOLFTbeta
Aptamer Sciences Inc

Aptamer Sciences Inc

291650 · KQ · Healthcare / Biotechnology

2,235.00KRW+20.00 (+0.90%)

Price History

Full chart

Market Stats

Previous Close2,215.00
Open2,315.00
Day Range2,200.00 – 2,315.00
52-Week Range1,350.00 – 3,996.00
Volume18.86K
Market Cap76.30B
P/E (TTM)0.00
Forward P/E0.00
Dividend Yield0.00%
Beta0.42
50-Day Avg1,798.62
200-Day Avg2,273.03

About

CHOOLIP & SCIENCES Inc., a bio venture company, focuses on the Aptamer technology platform for the development of therapeutic and diagnostic platforms. The company's platforms include aptamer discovery, optimization, and the development of therapeutics and diagnostics for cancer and neurological disorders. It offers AlloMAp and Bi-Functional Aptame (BiFAp) platform programs for therapeutics, as well as Aptodetect-lung, an early diagnosis kit for lung cancer. The company was formerly known as Aptamer Sciences Inc and changed its name to CHOOLIP & SCIENCES Inc. in August 2026. CHOOLIP & SCIENCES Inc. was founded in 2011 and is headquartered in Seongnam-si, South Korea.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEODr. Dongil Han
  • Employees0
  • Headquarters3-301, Seongnam-si, South Korea, 13487, Korea
  • Websitehttps://www.choolipscience.com

Leadership

  • Dr. Dongil HanChairman & CEO · b. 1959
  • Mr. Hyung-soon ParkChief Financial Officer · b. 1972
  • Dr. Sung Ho RyuCSO & Non-Executive Director · b. 1956
  • Mr. Gwang-yong LeeInside Director · b. 1967
  • Dr. Jeong-su YangHead of CRO Business Division · b. 1969

Financials

Income Statement

Currency: KRW2018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue276.50M407.59M228.51M269.28M358.25M243.19M1.08B3.50B
Growth (%)-+47.41%-43.94%+17.84%+33.04%-32.12%+345.26%+223.69%
Cost of Revenue1.21B1.21B1.20B1.35B1.58B1.86B2.72B1.81B
Gross Profit-934.61M-802.43M-974.38M-1.08B-1.22B-1.62B-1.63B1.69B
Gross Margin-338.02%-196.87%-426.41%-401.17%-341.00%-666.16%-150.94%48.23%
Operating Expense1.76B2.49B2.95B2.99B7.10B10.59B5.23B9.49B
Operating Income-2.69B-3.29B-3.92B-4.07B-8.32B-12.21B-6.87B-7.80B
Operating Margin-973.90%-807.56%-1716.79%-1510.39%-2322.35%-5019.47%-634.37%-222.57%
EBITDA-----7.50B-11.65B-6.47B-7.19B
EBITDA Margin-----2094.35%-4792.61%-597.92%-205.08%
Net Income-6.66B-3.85B-3.84B-3.83B-7.12B-13.60B-8.70B-8.62B
Net Income Margin-2409.38%-945.20%-1681.97%-1422.73%-1986.19%-5593.04%-803.68%-245.98%
R&D--1.77B1.76B6.03B9.36B3.14B3.36B
R&D as % of Total Revenue--774.59%654.91%1681.83%3848.33%290.39%95.73%
Interest Expense007.32M24.91M299.07M1.39B1.35B322.33M
Interest Expense % of Total Revenue0.00%0.00%3.20%9.25%83.48%573.25%124.50%9.20%

Balance Sheet

Currency: KRW2018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets10.99B8.32B36.93B33.26B45.65B32.54B31.98B41.11B
Total Liabilities29.25B1.38B1.75B1.80B16.42B17.06B6.54B12.87B
Total Equity-18.26B6.94B35.18B31.46B29.22B15.48B25.44B28.23B
Cash9.81B7.17B4.66B1.01B1.22B1.24B11.47B21.38B
Total Debt5.36B5.58M59.46M-----
Net Debt----5.62B6.99B--

Cash Flow

Currency: KRW2018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-2.10B-2.47B-3.41B-3.47B-5.78B-11.24B-5.90B-9.67B
Investing Cash Flow1.06B-205.11M-31.11B-57.99M-10.65B11.31B14.17B-
Financing Cash Flow9.80B40.63M32.01B-121.06M16.64B-62.62M1.97B-
Capital Expenditure367.85M197.97M349.37M7.09B308.88M299.76M1.14B20.49M
Free Cash Flow---3.78B-10.57B-6.08B-11.54B-7.04B-9.69B
FCF to OCF--110.75%304.12%105.35%102.67%119.36%100.21%

Earnings

Report DateSep 30, 2020Mar 17, 2021May 17, 2021Aug 17, 2021Nov 15, 2021Mar 21, 2022May 16, 2022Aug 16, 2022Nov 14, 2022Mar 22, 2023May 15, 2023Aug 14, 2023Nov 14, 2023Mar 28, 2024May 16, 2024Aug 14, 2024Nov 12, 2024Mar 12, 2025May 15, 2025Aug 12, 2025Nov 12, 2025Mar 17, 2026May 13, 2026Jun 30, 2026
EPS Estimate------------------------
EPS Actual-92.02-96.57-107.43-58.85-51.62-62.08-62.39-143.42-73.18-140.29-148.90-272.77-243.01-136.35-141.58-187.58-75.92-75.76-74.52-48.00-69.08-84.96-58.67-145.47
Surprise------------------------
Timing--After-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursPre-marketAfter-hoursAfter-hoursAfter-hoursAfter-hoursPre-marketPre-marketPre-marketPre-marketPre-market-

Key Statistics & Ratios

Market Cap76.30B
Enterprise Value51.65B
Trailing P/E0.00
Forward P/E0.00
Price / Sales10.26
Price / Book1.35
Revenue (TTM)1.08B
Gross Profit (TTM)772.00M
EBITDA-6.17B
Profit Margin0.00%
Operating Margin-128.89%
Return on Equity-42.54%
Return on Assets-13.66%
Shares Outstanding30.52M
Shares Float16.19M
Beta0.42
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Stock Splits

  • Aug 12, 20261:2
  • Oct 29, 2024914:747
  • Feb 28, 20232:1